The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function (LIRABONE)
The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.
Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
Estimated Enrollment: 60
Study Start Date: August 2015
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms:
Experimental: Liraglutide
Placebo Comparator: Placebo
Category | Value |
---|---|
Study start date | 2015-08-01 |